Journal
MABS
Volume 5, Issue 5, Pages 660-664Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.25428
Keywords
scFv-h3D6; immunotherapy; Alzheimer disease; cerebellum; DCN neurons
Categories
Funding
- MAEC-AECI fellowship (Spanish government)
- PIF (UAB, Spain) fellowship
- [FMM-2008]
- [FISPI10-00975]
- [FISPI10-00265]
- [FISPI10-00283]
- [SGR2009-00761]
- [SGR2009-42271]
Ask authors/readers for more resources
The therapeutic potential of scFv-h3D6 has recently been shown in the 3xTg-AD mice. A clear effect on amyloid (A) oligomers and certain apolipoproteins in the brain was found, but no effect was seen in the cerebellum. Here, cellular vulnerability of the 3xTg-AD cerebellum is described for the first time, together with its protection by scFv-h3D6. Neuron depletion in the DCN was regionally variable and followed a mediolateral axis of involvement that was greatest in the fastigial nucleus, lesser in the interpositus and negligible in the dentate nucleus. A sole and low intraperitoneal dose of scFv-h3D6 protected 3xTg-AD DCN neurons from death. Further studies might provide interesting information about both the potential of scFv-h3D6 as a therapeutic agent and the role of the cerebellum in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available